The effect of cyclosporine on expression of class II major histocompatibility complex antigens on bronchoalveolar cells and peripheral blood mononuclear cells.
To evaluate the effect of cyclosporine (CsA) on the expression of class II major histocompatibility complex (MHC) antigens on bronchoalveolar cells (BAC) and peripheral blood mononuclear cells (PBMC), BAC and PBMC were obtained from mongrel dogs before and during CsA treatment. Expression of MHC class II antigens on BAC and PBMC were detected by monoclonal antibodies (Mabs) B1F6, 7.5.10.1 and Q5/13, which recognized canine MHC class II antigens, using cytofluorometry. Total cell counts and cell differentials of canine BAC showed no significant difference before or during CsA treatment (P greater than 0.05). Anti-MHC class II Mabs used in this study reacted with 21-51% of canine BAC and with 31-69% of PBMC. After stimulation with phytohaemagglutinin (PHA) the percentages of MHC class II positive BAC and PBMC were significantly increased (P less than 0.001). Whole blood levels of CsA were 315 +/- 76 (mean +/- SD) ng/ml and 343 +/- 57 ng/ml on days 7 and 14 during CsA treatment at an oral dose of 20 mg/kg/day. During CsA treatment there was no significant difference in the percentages of MHC class II positive BAC and PBMC compared with data obtained before CsA treatment (P greater than 0.05). We likewise failed to observe a suppressive effect of CsA on the increased expression of MHC class II antigens on BAC and PBMC induced by PHA (P greater than 0.05). In summary, at an oral dose of 20 mg/kg/day for a period of two weeks, our results show that: (1) CsA does not affect the total cell counts and cell differentials of canine BAC; (2) CsA does not reduce the basal expression of MHC class II antigens on canine BAC and PBMC; (3) CsA does not suppress the increased expression of MHC class II antigens on canine BAC and PBMC induced by PHA.
Chang
S C
SC
Chest Department, Veterans' General Hospital, Taipei, Taiwan.
Perng
R P
RP
Shiao
G M
GM
Lin
C Y
CY
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D001980:Bronchi / Q000166:cytology / Q000276:immunology*; D002452:Cell Count / Q000187:drug effects; D003524:Cyclosporins / Q000494:pharmacology*; D004285:Dogs; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D000949:Histocompatibility Antigens Class II / Q000096:biosynthesis* / Q000235:genetics; D007963:Leukocytes, Mononuclear / Q000276:immunology*; D008213:Lymphocyte Activation; D008297:Male; D011650:Pulmonary Alveoli / Q000166:cytology / Q000276:immunology*
D000911:Antibodies, Monoclonal; D003524:Cyclosporins; D000949:Histocompatibility Antigens Class II